Business Context and Reporting Period
Company: Personalis, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 16, 2024
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities with Tempus AI, Inc.
Key Financial Metrics and Transaction Details
This filing details a capital raise and warrant exercise rather than standard periodic financial results. Key transaction metrics include:
- Common Stock Sale: Issued 3,500,000 shares at $5.07 per share.
- Gross Proceeds from Stock Sale: $17,745,000.
- Warrant Exercise: Tempus exercised warrants for 9,218,800 shares.
- Warrant Exercise Prices: 4,609,400 shares at $1.50/share and 4,609,400 shares at $2.50/share.
- Aggregate Proceeds from Warrant Exercise: $18,437,600.
- Total Cash Inflow from Transaction: $36,182,600.
Note: The filing text does not provide clear values for current period revenue, net profit, operating cash flow, margins, or total debt levels.
Material Changes and Agreements
Beyond the capital transaction, the Company amended its Commercialization and Reference Laboratory Agreement with Tempus. Material changes include:
- Termination Notice Period: Extended to 30 months for termination for convenience.
- Change of Control/Assignment: Added obligations regarding assignment to competitors or change of control transactions involving competitors.
- Capacity Commitments: Increased the number of new patients for which the Company commits to maintain laboratory capacity under certain circumstances.
Outlook, Risks, and Management Commentary
Management Commentary: The Company entered into these agreements to secure capital and strengthen its commercial relationship with Tempus. The Investment Agreement includes customary representations and warranties intended to allocate risk between the parties, which may not reflect the actual state of facts or conditions of the Company.
Risks and Contingencies:
- Registration Obligation: The Company must file a registration statement for the resale of the 3,500,000 shares within 30 calendar days of the sale.
- Contractual Obligations: The amended Commercialization Agreement imposes stricter terms regarding termination and capacity maintenance.
- Investor Reliance: Investors are cautioned not to rely on representations in the Investment Agreement as factual characterizations of the Company's condition.
Key Facts for Investor Verification
- Verify the total dilution impact of the 12,718,800 new shares issued (3.5M stock sale + 9.2M warrant exercise).
- Confirm the Company's ability to meet the 30-day deadline for filing the resale registration statement.
- Review the specific financial impact of the increased laboratory capacity commitments in the amended Commercialization Agreement.
- Assess the liquidity position of the Company post-transaction, noting the $36.2M in gross proceeds.